Zegalogue Mechanism of Action Buprenorphine – the active ingredient in Zegalogue is a partial agonist at the μ‑opioid receptor (MOR). Provides analgesia and a protective effect against opioid withdrawal. Ceiling effect on respiratory depression limits the risk in opioid‑naïve patients. Kappa‑opioid receptor (KOR) antagonist – contributes to a reduction in dysphoria and suicidality. ORL‑1 (nociceptin) … Read more
Zebeta Zebeta is a next‑generation β₂‑adrenergic receptor antagonist indicated primarily for the treatment of hypertension, angina pectoris, supraventricular tachycardia, migraine prophylaxis, and anxiety‑related tachycardia. Mechanism of Action Selective antagonism of β₂‑receptors on vascular smooth muscle and cardiac myocytes leads to: ⬇︎ Vasodilation (via inhibition of NO release) → lowered peripheral resistance. ↓ Heart rate and … Read more
Zarxio Mechanism of Action Zarxio functions as a selective JAK2/TYK2 inhibitor, binding to the ATP‑binding pocket of JAK2 and blocking phosphorylation of downstream STAT signaling pathways. Inhibition reduces transcription of pro‑inflammatory cytokines (IL‑6, IFN‑γ) and hampers proliferation of malignant hematopoietic clones, leading to decreased leukemic cell survival and reduced cytokine‑driven bone‑marrow exhaustion. Pharmacokinetics Bioavailability: ~45 % … Read more
Zanubrutinib Zanubrutinib (Brukinsa™) is a highly selective, irreversible Bruton’s Tyrosine Kinase (BTK) inhibitor used primarily in relapsed/refractory B‑cell malignancies and certain chronic lymphocytic leukemia (CLL) cases. — Mechanism of Action Selective irreversible inhibition of BTK, a key kinase in B‑cell receptor (BCR) signaling. Binds covalently to the cysteine 481 residue in BTK’s active site, blocking … Read more
Zantac Zantac (generic name ranitidine) is a histamine‑H₂ receptor antagonist that reduces gastric acid secretion. Although withdrawn from many markets due to contamination concerns, it remains available in certain countries; the following card provides a concise pharmacology overview. Mechanism of Action Competitive antagonist of histamine H₂ receptors on parietal cells in the stomach lining. Blocks … Read more
Zanaflex Zanaflex (tizanidine) is a short‑acting prescription medication used primarily to relieve muscle spasticity. It belongs to the class of α₂‑adrenergic agonists and offers a quick onset of action with a favorable safety profile when used appropriately. Mechanism of Action Selective α₂‑adrenergic agonist: Enhances inhibitory α₂‑receptor activity in the spinal cord, which ↓ the excitability … Read more
Zaleplon Zaleplon (brand name Sonata) is a short‑acting hypnotic of the benzodiazepine receptor agonist class used for the acute treatment of insomnia. Mechanism of Action Zaleplon acts as a positive allosteric modulator at the γ‑aminobutyric acid A (GABAA) receptor complex. It preferentially binds to the benzodiazepine site, enhancing GABA‑mediated chloride influx and neuronal hyperpolarization. Its … Read more
Yuvafem Yuvafem is a low‑dose oral estrogen‑phytoestrogen combination used primarily for the relief of menopausal symptoms and the prevention of osteoporotic fractures in estrogen‑deficient women. Mechanism of Action Low‑dose 17‑β‑estradiol (3 µg): Replaces declining endogenous estrogen, binding to nuclear estrogen receptors (ERα/ERβ). Restores transcription of estrogen‑responsive genes in vaginal epithelial cells, bone, and the cardiovascular system. … Read more
Yutrepia Yutrepia is a recently approved oral small‑molecule inhibitor that selectively targets Janus kinase pathways. Its design balances potency against JAK1/JAK3 with a favorable safety profile, making it a compelling option for immune‑mediated disorders. Mechanism of Action Selective JAK1/JAK3 inhibition: Blocks phosphorylation of STATs downstream of cytokine receptors (IL‑6, IFN‑γ, IL‑2, etc.), thereby dampening aberrant … Read more
Yusimry Yusimry is a recently developed oral therapeutic agent currently in late‑phase clinical development. It is being investigated for the treatment of moderate‑to‑severe chronic inflammatory disorders such as ulcerative colitis and rheumatoid arthritis. The following drug card summarizes its pharmacologic profile, clinical data, and practical prescribing guidance. — Mechanism of Action Selective PPAR‑β/δ agonist that … Read more